Pharmafile Logo
Pharmafocus logo
Advanced Search
alvogen_drugs_generic

Alvogen buys four-drug portfolio from Pfizer

August 27, 2015
Sales and Marketing Alvogen, Pfizer

Alvogen has entered into a agreement with Pfizer to purchase a portfolio of four pharmaceutical products for the US market, …

News
cml

NHS restriction of CML treatment in England criticised

August 27, 2015
Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia

Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …

News
md_anderson_cancer_center

Immatics and MD Anderson launch new company to develop ACR therapies

August 27, 2015
Research and Development, Sales and Marketing Cancer, MD Anderson Cancer Center, immatics, keytruda

Immatics Biotechnologies and The University of Texas MD Anderson Cancer Center (MDACC) have together launched a new company focusing on …

News
diabetes_injection

NICE targets tight blood sugar control in new diabetes guidelines

August 27, 2015
NICE, NICE guidelines, Public Health England, Type 1 diabetes, diabetes

NICE has urged healthcare professionals to target tighter blood sugar control, in a suite of recommendation in updated guidelines on …

News
alimta

Lilly defeats Teva in US court over Alimta patent

August 26, 2015
Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer

Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …

News
artist's impression

Novo Nordisk plans $2bn expansion of production facilities

August 26, 2015
Manufacturing and Production, Research and Development Novo Nordisk, manufacturing

Novo Nordisk will invest an estimated $2 billion over the next five years in new production facilities in the US, …

News
crossroads

After the legal case – where next for pharma industry transparency?

August 26, 2015
Research and Development clinical trial transparency, clinical trials, health research authority, transparency

Even in an industry as litigious as pharma can sometimes be, the recent legal drama that has played out in …

Feature
novonordiskhq

Novo Nordisk abandons Victoza submission after mixed T1D results

August 26, 2015
Research and Development Novo Nordisk, Victoza, diabetes, insulin

Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …

News
Ebola virus

Researchers hopeful experimental antiviral treatment stops Ebola

August 26, 2015
Research and Development Ebola, Ebola virus, Ebola virus disease, Toyama Chemical, VSV-ZEBOV, favipiravir, zmapp

An experimental antiviral therapy may have prevented British healthcare workers from contracting Ebola after exposure to the disease in West …

News
Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

News
swine flu virus

TSRI and Janssen close in on universal flu vaccine

August 25, 2015
Manufacturing and Production Janssen, Vaccine, flu, immunology, universal flu vaccine

Scientists from Janssen and The Scripps Research Institute (TSRI) have found a way to induce antibodies to fight a wide …

News
Allergan

Allergan recalls eye drugs after complaints of blurred vision

August 25, 2015
Manufacturing and Production Allergan, manufacturing, product recalls, production, recalls

Allergan has issued a recall for batches of eye ointments sold in the US, after customers complained of foreign bodies …

News
Takeda oncology

Takeda in Velcade patent blow

August 25, 2015
Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib

Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …

News
sean_bohen

AZ appoints Genentech’s Sean Bohen as chief medical officer

August 25, 2015
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Briggs Morrison, Sean Bohen

AstraZeneca has appointed Dr Sean Bohen as executive vice president of global medicines development and chief medical officer.Dr Bohen will …

Appointment

Clinical Trial Transparency – A Personal View

August 24, 2015
Research and Development ABPI, PMCPA, clinical trial transparency, clinical trials, health research authority, transparency

During the time I worked as research, medical and innovation director at the ABPI, between October 2012 and January 2015, …

Feature
research lab

AstraZeneca cancer drug trialled for pancreatic cancer

August 24, 2015
Research and Development

AstraZeneca is working with the Banner MD Anderson Cancer Center in Arizona to test its cancer drug Lynparza as a …

News
Logos

AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015
Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

News
Health secretary Jeremy Hunt

Doctors ‘face jail over pharma payments’

August 24, 2015
Sales and Marketing ABPI, Jeremy Hunt, NHS, PMCPA, bribery, doctor payments, health secretary, transparency

Healthcare professionals who have inappropriate financial links with pharma companies will face prosecution and up to 10 years in jail, …

News

Takeda gets European MAA approval for ixazomib

August 21, 2015
Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma

Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …

News
novartis

Novartis buys rights to GSK MS drug for up to $1 billion

August 21, 2015
Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab

Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …

News
The Gateway to Local Adoption Series

Latest content

Sandoz opens biosimilar development centre in Slovenia

June 19, 2026

Codis announces three senior business development appointments

June 18, 2026

US laboratory approval supports launch of lung cancer blood test

June 17, 2026

Study to examine ways of improving diabetes care for younger adults

June 16, 2026

Phase 2 endometriosis trial reaches recruitment milestone

June 15, 2026